393 related articles for article (PubMed ID: 24311635)
21. Potent antitumour of the mTORC1/2 dual inhibitor AZD2014 in docetaxel-sensitive and docetaxel-resistant castration-resistant prostate cancer cells.
Li S; Sheng J; Liu Z; Fan Y; Zhang C; Lv T; Hu S; Jin J; Yu W; Song Y
J Cell Mol Med; 2021 Mar; 25(5):2436-2449. PubMed ID: 33507584
[TBL] [Abstract][Full Text] [Related]
22. Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: the discovery of AZD8055 and AZD2014.
Pike KG; Malagu K; Hummersone MG; Menear KA; Duggan HM; Gomez S; Martin NM; Ruston L; Pass SL; Pass M
Bioorg Med Chem Lett; 2013 Mar; 23(5):1212-6. PubMed ID: 23375793
[TBL] [Abstract][Full Text] [Related]
23. Preclinical analysis of MTOR complex 1/2 inhibition in diffuse intrinsic pontine glioma.
Flannery PC; DeSisto JA; Amani V; Venkataraman S; Lemma RT; Prince EW; Donson A; Moroze EE; Hoffman L; Levy JMM; Foreman N; Vibhakar R; Green AL
Oncol Rep; 2018 Feb; 39(2):455-464. PubMed ID: 29207163
[TBL] [Abstract][Full Text] [Related]
24. Investigation of the novel mTOR inhibitor AZD2014 in neuronal ischemia.
Hadley G; Beard DJ; Alexopoulou Z; Sutherland BA; Buchan AM
Neurosci Lett; 2019 Jul; 706():223-230. PubMed ID: 31100427
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of DNA double-strand break repair by the dual PI3K/mTOR inhibitor NVP-BEZ235 as a strategy for radiosensitization of glioblastoma.
Gil del Alcazar CR; Hardebeck MC; Mukherjee B; Tomimatsu N; Gao X; Yan J; Xie XJ; Bachoo R; Li L; Habib AA; Burma S
Clin Cancer Res; 2014 Mar; 20(5):1235-48. PubMed ID: 24366691
[TBL] [Abstract][Full Text] [Related]
26. Influence of the Novel ATP-Competitive Dual mTORC1/2 Inhibitor AZD2014 on Immune Cell Populations and Heart Allograft Rejection.
Fantus D; Dai H; Ono Y; Watson A; Yokota S; Mohib K; Yoshida O; Ross MA; Watkins SC; Ramaswami B; Valusjkikh A; Rothstein DM; Thomson AW
Transplantation; 2017 Dec; 101(12):2830-2840. PubMed ID: 28885497
[TBL] [Abstract][Full Text] [Related]
27. Synergistic induction of apoptosis by combination of BTK and dual mTORC1/2 inhibitors in diffuse large B cell lymphoma.
Ezell SA; Mayo M; Bihani T; Tepsuporn S; Wang S; Passino M; Grosskurth SE; Collins M; Parmentier J; Reimer C; Byth KF
Oncotarget; 2014 Jul; 5(13):4990-5001. PubMed ID: 24970801
[TBL] [Abstract][Full Text] [Related]
28. Targeting MPS1 Enhances Radiosensitization of Human Glioblastoma by Modulating DNA Repair Proteins.
Maachani UB; Kramp T; Hanson R; Zhao S; Celiku O; Shankavaram U; Colombo R; Caplen NJ; Camphausen K; Tandle A
Mol Cancer Res; 2015 May; 13(5):852-62. PubMed ID: 25722303
[TBL] [Abstract][Full Text] [Related]
29. The mTOR kinase inhibitors, CC214-1 and CC214-2, preferentially block the growth of EGFRvIII-activated glioblastomas.
Gini B; Zanca C; Guo D; Matsutani T; Masui K; Ikegami S; Yang H; Nathanson D; Villa GR; Shackelford D; Zhu S; Tanaka K; Babic I; Akhavan D; Lin K; Assuncao A; Gu Y; Bonetti B; Mortensen DS; Xu S; Raymon HK; Cavenee WK; Furnari FB; James CD; Kroemer G; Heath JR; Hege K; Chopra R; Cloughesy TF; Mischel PS
Clin Cancer Res; 2013 Oct; 19(20):5722-32. PubMed ID: 24030701
[TBL] [Abstract][Full Text] [Related]
30. Synergistic Effects between mTOR Complex 1/2 and Glycolysis Inhibitors in Non-Small-Cell Lung Carcinoma Cells.
Jiang S; Zou Z; Nie P; Wen R; Xiao Y; Tang J
PLoS One; 2015; 10(7):e0132880. PubMed ID: 26176608
[TBL] [Abstract][Full Text] [Related]
31. Microenvironmental regulation of glioblastoma radioresponse.
Jamal M; Rath BH; Williams ES; Camphausen K; Tofilon PJ
Clin Cancer Res; 2010 Dec; 16(24):6049-59. PubMed ID: 21037023
[TBL] [Abstract][Full Text] [Related]
32. TP53 mutated glioblastoma stem-like cell cultures are sensitive to dual mTORC1/2 inhibition while resistance in TP53 wild type cultures can be overcome by combined inhibition of mTORC1/2 and Bcl-2.
Venkatesan S; Hoogstraat M; Caljouw E; Pierson T; Spoor JK; Zeneyedpour L; Dubbink HJ; Dekker LJ; van der Kaaij M; Kloezeman J; Berghauser Pont LM; Besselink NJ; Luider TM; Joore J; Martens JW; Lamfers ML; Sleijfer S; Leenstra S
Oncotarget; 2016 Sep; 7(36):58435-58444. PubMed ID: 27533080
[TBL] [Abstract][Full Text] [Related]
33. MLN0128, an ATP-competitive mTOR kinase inhibitor with potent in vitro and in vivo antitumor activity, as potential therapy for bone and soft-tissue sarcoma.
Slotkin EK; Patwardhan PP; Vasudeva SD; de Stanchina E; Tap WD; Schwartz GK
Mol Cancer Ther; 2015 Feb; 14(2):395-406. PubMed ID: 25519700
[TBL] [Abstract][Full Text] [Related]
34. CC-223, a Potent and Selective Inhibitor of mTOR Kinase: In Vitro and In Vivo Characterization.
Mortensen DS; Fultz KE; Xu S; Xu W; Packard G; Khambatta G; Gamez JC; Leisten J; Zhao J; Apuy J; Ghoreishi K; Hickman M; Narla RK; Bissonette R; Richardson S; Peng SX; Perrin-Ninkovic S; Tran T; Shi T; Yang WQ; Tong Z; Cathers BE; Moghaddam MF; Canan SS; Worland P; Sankar S; Raymon HK
Mol Cancer Ther; 2015 Jun; 14(6):1295-305. PubMed ID: 25855786
[TBL] [Abstract][Full Text] [Related]
35. Combined inhibition of AKT/mTOR and MDM2 enhances Glioblastoma Multiforme cell apoptosis and differentiation of cancer stem cells.
Daniele S; Costa B; Zappelli E; Da Pozzo E; Sestito S; Nesi G; Campiglia P; Marinelli L; Novellino E; Rapposelli S; Martini C
Sci Rep; 2015 Apr; 5():9956. PubMed ID: 25898313
[TBL] [Abstract][Full Text] [Related]
36. The preclinical evaluation of the dual mTORC1/2 inhibitor INK-128 as a potential anti-colorectal cancer agent.
Li C; Cui JF; Chen MB; Liu CY; Liu F; Zhang QD; Zou J; Lu PH
Cancer Biol Ther; 2015; 16(1):34-42. PubMed ID: 25692620
[TBL] [Abstract][Full Text] [Related]
37. In vitro and in vivo radiosensitization with AZD6244 (ARRY-142886), an inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2 kinase.
Chung EJ; Brown AP; Asano H; Mandler M; Burgan WE; Carter D; Camphausen K; Citrin D
Clin Cancer Res; 2009 May; 15(9):3050-7. PubMed ID: 19366835
[TBL] [Abstract][Full Text] [Related]
38. Radiation Drives the Evolution of Orthotopic Xenografts Initiated from Glioblastoma Stem-like Cells.
McAbee JH; Rath BH; Valdez K; Young DL; Wu X; Shankavaram UT; Camphausen K; Tofilon PJ
Cancer Res; 2019 Dec; 79(23):6032-6043. PubMed ID: 31615806
[TBL] [Abstract][Full Text] [Related]
39. A Kinase Inhibitor Targeted to mTORC1 Drives Regression in Glioblastoma.
Fan Q; Aksoy O; Wong RA; Ilkhanizadeh S; Novotny CJ; Gustafson WC; Truong AY; Cayanan G; Simonds EF; Haas-Kogan D; Phillips JJ; Nicolaides T; Okaniwa M; Shokat KM; Weiss WA
Cancer Cell; 2017 Mar; 31(3):424-435. PubMed ID: 28292440
[TBL] [Abstract][Full Text] [Related]
40. A dual mTORC1 and mTORC2 inhibitor shows antitumor activity in esophageal squamous cell carcinoma cells and sensitizes them to cisplatin.
Huang Y; Xi Q; Chen Y; Wang J; Peng P; Xia S; Yu S
Anticancer Drugs; 2013 Oct; 24(9):889-98. PubMed ID: 23838676
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
